Skip to content

A Randomised Phase II/III Trial to Explore the Repetitive Transcranial Magnetic Stimulation on the Effects of Hypothalamic-Pituitary-Adrenal Axis of Patients with Depression

A Double-Blind Randomized Phase II/III Trial of Daily to Compare Sleep Electroencephalogram-Modulated Repetitive Transcranial Magnetic Stimulation(rTMS) with Conventional rTMS and Sham rTMS for Depressio

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-09000465
Enrollment
Unknown
Registered
2009-06-29
Start date
2007-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression disorder

Interventions

A:Sleep electroencephalogram-modulated repetitive transcranial magnetic stimulation
B:Conventional repetitive transcranial magnetic stimulation
C:Sham repetitive transcranial magnetic stimulation

Sponsors

Lianyungang Hospital Affiliated to Medical College of Xuzhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 76 Years

Inclusion criteria

Inclusion criteria: 1. Age of 12 to 76 years old, male or female; 2. Depression was diagnosed according to the diagnostic criteria of the Diagnostic and Statistical Manual 3th edition (DSM-III); 3.The subjects or their guardian signed a study consent form before enrollment.

Exclusion criteria

Exclusion criteria: 1. Organic mental disorder based on the following criteria: Computed tomography and/or magnetic resonance imaging showed evidence of organic nervous system lesions; nervous system examination revealed organic central nervous system lesions; history of stroke, cerebral hemorrhage, poisoning or other serious central nervous system disease or sequelae of a serious mental disorder caused by organic diseases of other systems; 2. Psychoactive substance- or nonaddictive substance-induced depression; 3. Refusal of medical treatment; 4. Association with other mental illness and strong tendency for suicide; 5. Unable to stop drug treatment because of a physical disease.

Design outcomes

Primary

MeasureTime frame
HADM scores;Concentration of ACTH and COR;

Countries

China

Contacts

Public ContactMingli He
hemingli668@163.com+86 0518 85605197

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026